Is aspirin worth it in the under-70s?

Twice as many CVD events averted as bleeds in five years, say researchers

Doctors can be reassured that the benefits outweigh the potential harms in recommending aspirin to the under-70s to prevent cardiovascular disease (CVD) events, New Zealand researchers say.

Their study finds that the number of CVD events averted is estimated to be more than twice the number of major bleeds expected to be caused by aspirin over five years.

“These data provide assurance to clinicians and patients regarding the use of aspirin for primary prevention,” the authors write in the New Zealand Medical Journal.

“Among people aged less than 70 years with estimated five-year CVD risk of [greater than] 15% and no other indications for, or contraindications/cautions to aspirin use, the number of CVD events avoided are estimated to exceed the number of additional major bleeds, whether or not lipid- and blood pressure-lowering therapy need to be added and/or optimised.”

However, they say